Recursion Pharmaceuticals Net Worth
Recursion Pharmaceuticals Net Worth Breakdown | RXRX |
Recursion Pharmaceuticals Net Worth Analysis
Recursion Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Recursion Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Recursion Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Recursion Pharmaceuticals' net worth analysis. One common approach is to calculate Recursion Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Recursion Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Recursion Pharmaceuticals' net worth. This approach calculates the present value of Recursion Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Recursion Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Recursion Pharmaceuticals' net worth. This involves comparing Recursion Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Recursion Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Recursion Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Recursion Pharmaceuticals' net worth research are outlined below:
| Recursion Pharmaceuticals generated a negative expected return over the last 90 days | |
| Recursion Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 44.58 M. Net Loss for the year was (328.07 M) with loss before overhead, payroll, taxes, and interest of (164.13 M). | |
| Recursion Pharmaceuticals currently holds about 515.44 M in cash with (287.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98. | |
| Roughly 69.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: 2 Innovative Stocks That Could Deliver Outsize Returns |
Recursion Pharmaceuticals Quarterly Good Will |
|
Recursion Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Recursion Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Recursion Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Recursion Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Recursion Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Recursion Pharmaceuticals backward and forwards among themselves. Recursion Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Recursion Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nvidia Corp | 2024-06-30 | 7.7 M | Data Collective Iv Gp, Llc | 2024-09-30 | 5.9 M | Geode Capital Management, Llc | 2024-06-30 | 4.8 M | Dcvc Opportunity Fund Ii Gp, Llc | 2024-06-30 | 4 M | Exor Investments (uk) Llp | 2024-06-30 | 3.7 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3.5 M | Laurion Capital Management Lp | 2024-06-30 | 2.9 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 2.1 M | Northern Trust Corp | 2024-09-30 | 2 M | Ark Investment Management Llc | 2024-06-30 | 28.1 M | Baillie Gifford & Co Limited. | 2024-09-30 | 25.2 M |
Follow Recursion Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.22 B.Market Cap |
|
Project Recursion Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.62) | (0.66) | |
| Return On Assets | (0.50) | (0.53) | |
| Return On Equity | (0.71) | (0.67) |
When accessing Recursion Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Recursion Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Recursion Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Recursion Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Recursion Pharmaceuticals. Check Recursion Pharmaceuticals' Beneish M Score to see the likelihood of Recursion Pharmaceuticals' management manipulating its earnings.
Evaluate Recursion Pharmaceuticals' management efficiency
Recursion Pharmaceuticals has return on total asset (ROA) of (0.364) % which means that it has lost $0.364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7849) %, meaning that it created substantial loss on money invested by shareholders. Recursion Pharmaceuticals' management efficiency ratios could be used to measure how well Recursion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Recursion Pharmaceuticals' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 226.3 M in 2024, whereas Total Assets are likely to drop slightly above 520.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.23 | 2.34 | |
| Tangible Book Value Per Share | 1.80 | 0.92 | |
| Enterprise Value Over EBITDA | (5.70) | (5.99) | |
| Price Book Value Ratio | 4.42 | 4.64 | |
| Enterprise Value Multiple | (5.70) | (5.99) | |
| Price Fair Value | 4.42 | 4.64 | |
| Enterprise Value | 1.7 B | 1.9 B |
The strategic initiatives led by Recursion Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 29.0865 | Revenue 65.2 M | Quarterly Revenue Growth 1.476 | Revenue Per Share 0.265 | Return On Equity (0.78) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Recursion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Recursion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Recursion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Recursion Pharmaceuticals Corporate Filings
F3 | 22nd of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 20th of November 2024 Other Reports | ViewVerify | |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Recursion Pharmaceuticals Earnings per Share Projection vs Actual
Recursion Pharmaceuticals Corporate Management
| Christopher Gibson | CEO CoFounder | Profile | |
| Kevin Leggat | Vice Accounting | Profile | |
| Janelle Gordon | Vice Operations | Profile | |
| Shafique MD | Interim Officer | Profile | |
| Nathan Hatfield | Chief Officer | Profile | |
| MBA JD | Chief Counsel | Profile |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.